Loading...
•
Jun 30, 2022
Editas Q2 2022 Earnings Report
Editas Medicine reported a net loss for Q2 2022 and provided updates on its clinical programs and collaborations.
Key Takeaways
Editas Medicine reported a net loss of $53.5 million for the second quarter of 2022, compared to a net loss of $55.3 million for the same period in 2021. The company's cash, cash equivalents, and marketable securities totaled $527.6 million as of June 30, 2022, which is expected to fund operations into 2024. Editas continues to advance its gene editing programs, including EDIT-301 for sickle cell disease and EDIT-101 for LCA10.
Successful engraftment achieved in first patient treated with EDIT-301 for sickle cell disease.
FDA removed partial clinical hold for RUBY trial of EDIT-301.
Continued screening and enrolling patients for EDIT-101 Phase 1/2 BRILLIANCE study for LCA10, with clinical data update expected in the second half of 2022.
Collaboration with Immatics to develop cancer medicines using gamma-delta T cell adoptive cell therapies and gene editing.
Revenue by Segment
Forward Guidance
Editas Medicine expects its existing cash, cash equivalents and marketable securities will enable it to fund its operating expenses and capital expenditures into 2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...